2015年4月29日,由美国Kythera生物制药公司研发的去氧胆酸(deoxycholic acid)经美国食品和药品监督管理局(FDA)批准上市,商品名为Kybella,其剂型为注射液[1]。去氧胆酸注射液用于成年人中度至重度凸起的丰满颏下脂肪外观的改善[1]。去氧胆酸的中文化学名称为:(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-二羟基-10,13-二甲基十 On April 29, 2015, deoxycholic acid developed by the Kythera Biopharmaceuticals Company of the United States was approved by the U.S. Food and Drug Administration (FDA) under the trade name Kybella for injection [1] . Deoxycholic acid injection for adults with moderate to severe raised submental fatty subcutaneous appearance of improvement [1]. The Chinese chemical name for deoxycholic acid is: (R) -4 - ((3R, 5R, 8R, 9S, 10S, 12S, 13R, 14S, 17R) -3,12-dihydroxy-10,13- Base ten